VANCOUVER, British Columbia & GRAPEVINE, Texas–(BUSINESS WIRE)–Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a business update. “The third quarter was our strongest quarter since the launch of ZUNVEYL, the first new oral Alzheimer’s treatment
